Holen Sie sich die Stockscreener-App
2.04
1.92%
-0.04
Vorhandelsmarkt:
2.07
0.03
+1.47%
Schlusskurs vom Vortag:
$2.08
Offen:
$2.08
24-Stunden-Volumen:
1.67M
Relative Volume:
0.55
Marktkapitalisierung:
$698.85M
Einnahmen:
$796.85M
Nettoeinkommen (Verlust:
$30.44M
KGV:
24.23
EPS:
0.0842
Netto-Cashflow:
$93.88M
1W Leistung:
-8.52%
1M Leistung:
-13.92%
6M Leistung:
-48.87%
1J Leistung:
-56.03%
1-Tages-Spanne:
$2.0337
$2.095
1-Wochen-Bereich:
$2.00
$2.22
52-Wochen-Spanne:
$1.77
$5.8099
Goodrx Holdings Inc Stock (GDRX) Company Profile
Firmenname
Goodrx Holdings Inc
Sektor
Branche
Telefon
(855) 268-2822
Adresse
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, TEM, BTSG, HQY, WAY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
2.04 | 698.85M | 796.85M | 30.44M | 93.88M | 0.0842 |
VEEV
Veeva Systems Inc
|
179.11 | 29.44B | 3.20B | 908.91M | 1.39B | 5.4168 |
TEM
Tempus Ai Inc
|
48.83 | 8.73B | 1.27B | -245.03M | -245.36M | -1.4071 |
BTSG
Brightspring Health Services Inc
|
43.31 | 8.32B | 12.91B | 104.80M | 394.69M | 0.8769 |
HQY
Healthequity Inc
|
82.10 | 6.94B | 1.31B | 215.20M | 408.32M | 2.4627 |
WAY
Waystar Holding Corp
|
24.03 | 4.61B | 1.10B | 112.09M | 283.19M | 0.6096 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-27 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2026-01-22 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-09 | Eingeleitet | Barclays | Underweight |
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-08-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-08-10 | Hochstufung | DA Davidson | Neutral → Buy |
| 2023-07-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Eingeleitet | Citigroup | Buy |
| 2022-11-04 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-12 | Eingeleitet | DA Davidson | Neutral |
| 2022-06-10 | Herabstufung | Goldman | Buy → Neutral |
| 2022-06-06 | Fortgesetzt | BofA Securities | Buy |
| 2022-06-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-03-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Bestätigt | Barclays | Overweight |
| 2022-03-01 | Bestätigt | BofA Securities | Neutral |
| 2022-03-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-01 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Bestätigt | Evercore ISI | Outperform |
| 2022-03-01 | Bestätigt | Goldman | Buy |
| 2022-03-01 | Bestätigt | JP Morgan | Underweight |
| 2022-03-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-03-01 | Bestätigt | SVB Leerink | Outperform |
| 2022-01-07 | Eingeleitet | Goldman | Buy |
| 2021-12-21 | Eingeleitet | Stephens | Overweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-08-31 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Guggenheim | Buy |
| 2020-11-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Eingeleitet | Barclays | Equal Weight |
| 2020-10-19 | Eingeleitet | BofA Securities | Neutral |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-10-19 | Eingeleitet | Credit Suisse | Outperform |
| 2020-10-19 | Eingeleitet | Deutsche Bank | Hold |
| 2020-10-19 | Eingeleitet | Goldman | Neutral |
| 2020-10-19 | Eingeleitet | JP Morgan | Neutral |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-10-19 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2020-10-19 | Eingeleitet | UBS | Buy |
Alle ansehen
Goodrx Holdings Inc Aktie (GDRX) Neueste Nachrichten
How The Reset In Expectations Is Reframing The GoodRx Holdings (GDRX) Investment Story - Yahoo Finance
If You Invested $1,000 in Goodrx Holdings, Inc. (GDRX) - Stock Titan
Dow Update: Can GoodRx Holdings Inc expand its profit margins2026 Final Week & Weekly Hot Stock Watchlists - baoquankhu1.vn
GoodRx Holdings, Inc. Announces Dismissal of PwC as Independent Auditor in March 2026 - Minichart
GoodRx (GDRX) replaces PwC with KPMG as independent auditor for 2026 - Stock Titan
Morgan Stanley favors GoodRx (GDRX) and healthcare tech over managed care for 2026 citing strong market-beating potential - MSN
GoodRx stock ticks up after launching weight-loss subscription service - MSN
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Strategy Pivot Hits GoodRx - Los Angeles Business Journal
Lakewood Capital Management LP Decreases Position in GoodRx Holdings, Inc. $GDRX - MarketBeat
GoodRx (GDRX) director exercises 192K options and gifts 150K Class A shares - Stock Titan
GoodRx Holdings, Inc.Class A Common Stock (NQ: GDRX - The Chronicle-Journal
Published on: 2026-03-12 03:47:43 - baoquankhu1.vn
GoodRx (NASDAQ:GDRX) Shares Down 6%Time to Sell? - MarketBeat
GoodRx Holdings, Inc. announced that consumers paying with cash through its platform can enjoy up to 85% discounts on medications at more than 70,000 pharmacies across the United States. - Bitget
GoodRx (GDRX) Partners with Viatris for Major Medication Discoun - GuruFocus
GoodRx offers up to 85% discount on Viatris drugs (GDRX) - Seeking Alpha
GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications - ChartMill
GoodRx (GDRX) CAO converts RSUs to stock and withholds shares for taxes - Stock Titan
GoodRx: Losing Relevance With Consumers (Downgrade) (NASDAQ:GDRX) - Seeking Alpha
GoodRx (GDRX) Q4 2025 Earnings Call Transcript - AOL.com
Aug Technicals: How does GoodRx Holdings Inc perform in inflationary periods2025 Investor Takeaways & Verified Momentum Stock Ideas - baoquankhu1.vn
Aug Reactions: Is GoodRx Holdings Inc showing insider buyingMarket Movement Recap & Short-Term High Return Ideas - baoquankhu1.vn
GoodRx awards discretionary cash bonus to chief accounting officer - Investing.com UK
GoodRx awards discretionary cash bonus to chief accounting officer By Investing.com - Investing.com South Africa
GoodRx Awards Performance-Based Bonus to Chief Accounting Officer - TipRanks
GoodRx approves $72,918 discretionary bonus for Chief Accounting Officer Romin Nabiey - TradingView
GoodRx (GDRX) Board approves $72,918 bonus for Chief Accounting Officer - Stock Titan
U.S. medical discount service provider GoodRx Holdings, Inc. recently announced the launch of an innovative subsidy program for self-insured employers. - Bitget
GoodRx to expand employer-sponsored access to Zepbound® Kwikpen® - marketscreener.com
Obesity drug Zepbound now offered to workers at $449 through GoodRx - Stock Titan
[Form 4] GoodRx Holdings, Inc. Insider Trading Activity - Stock Titan
GoodRx (NASDAQ: GDRX) grants 1.33M RSUs to director Wendy Barnes - Stock Titan
GDRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
GDRX: Wells Fargo Maintains Rating, Lowers Price Target by 50% | - GuruFocus
Wells Fargo & Company Has Lowered Expectations for GoodRx (NASDAQ:GDRX) Stock Price - MarketBeat
GoodRx Holdings (GDRX) Analyst Rating Update: Citigroup Lowers P - GuruFocus
Citigroup Lowers GoodRx (NASDAQ:GDRX) Price Target to $3.50 - MarketBeat
GoodRx Holdings, Inc. (GDRX) Stock Analysis: A 51.74% Upside Potential Awaits Investors - DirectorsTalk Interviews
GDRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
GoodRx (NASDAQ:GDRX) Trading Up 9.4%Should You Buy? - MarketBeat
The Goldman Sachs Group Lowers GoodRx (NASDAQ:GDRX) Price Target to $2.50 - MarketBeat
Goldman Sachs Lowers GoodRx Holdings (GDRX) Price Target to $2.5 - GuruFocus
Goodrx Holdings Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
GoodRx Earnings Call Marks Transitional Reset Year - TipRanks
GoodRx Announces Resignation of Board Member Dipanjan Deb - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX) and Vericel (VCEL) - The Globe and Mail
Assessing GoodRx Holdings (GDRX) Valuation After Employer Direct Launch And Post Earnings Analyst Shifts - simplywall.st
Why GoodRx (GDRX) Is Down 19.4% After Unveiling Employer Direct And 2026 Revenue Guidance - Yahoo Finance
GoodRx (GDRX) board member Dipanjan Deb steps down without dispute - Stock Titan
GoodRx Holdings (GDRX) Analyst Rating and Price Target Update | - GuruFocus
Finanzdaten der Goodrx Holdings Inc-Aktie (GDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.50%
2.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):